Neurocrine biosciences announces initiation of phase 1 clinical study evaluating effects of nbi-1117570 in healthy adults

San diego , sept. 11, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix), today announced the initiation of its phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound nbi-1117570 in healthy adult participants.
NBIX Ratings Summary
NBIX Quant Ranking